Explore the unique mechanisms of bispecific antibodies versus CAR T-cell therapies in treating multiple myeloma and their clinical implications. In this episode, experts begin outlining how bispecific ...
The MarketWatch News Department was not involved in the creation of this content. -- Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results